How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

With students today using AI for their learning, teachers can actually teach how to use technology as a collaborative tutor to practise skills, explain complex algorithms, and provide instant feedback ...

Learning to program in C on an online platform can provide structured learning and a certification to show along with your resume. Learning C can still be useful in 2026, especially if you want to ...

Executive function describes a set of cognitive processes and mental skills that help an individual plan, monitor, and successfully execute their goals. The “executive functions,” as they’re known, ...

A buffer overflow happens when a program writes more data into a memory buffer than the buffer can hold. The extra bytes land in adjacent memory, corrupting whatever was there. If an attacker controls ...

Thyroid function tests are blood tests that measure hormone levels to check how well your thyroid is working. The most common tests are thyroid-stimulating hormone (TSH) and thyroxine (T4), which help ...

Forbes contributors publish independent expert analyses and insights. Dr. Lance B. Eliot is a world-renowned AI scientist and consultant. This voice experience is generated by AI. Learn more. This ...

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

On June 24, 2026, Microsoft’s Digital Crimes Unit (DCU) facilitated the takedown, suspension, and blocking of domains that ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.